Big Gain For Aravive, Inc.
Mon, Oct 31, 2022 at 07:28 PM
Aravive, Inc. (ARAV:NASDAQ) soared at $1.31, a gain of 23.6%. On Mon, Oct 31, 2022, ARAV:NASDAQ hit a New 2-Week High of $1.31. The stock got featured on our News Catalysts scanner on Tue, Oct 25, 2022 at 09:12 AM in the 'PRIVATE PLACEMENT' category. From Mon, Oct 17, 2022, the stock recorded 60.00% Up Days and 45.45% Green Days
About Aravive, Inc. (ARAV:NASDAQ)
Versartis Inc is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency.
Top 10 Gainers:
- Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 66.38%
- Acorda Therapeutics, Inc. (ACOR:NASDAQ), 63.36%
- Bull Horn Holdings Corp. (BHSE:NASDAQ), 44.67%
- Actinium Pharmaceuticals, Inc. (ATNM:NYSEMKT), 39.16%
- Shineco Inc. (SISI:NASDAQ), 37.96%
- Getty Images Holdings Inc. Class A (GETY:NYSE), 34.65%
- Sientra, Inc. (SIEN:NASDAQ), 31.11%
- Renovare Environmental Inc. (RENO:NASDAQ), 28.57%
- Aravive, Inc. (ARAV:NASDAQ), 23.58%
- Mondee Holdings Inc. (MOND:NASDAQ), 22.46%